These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21625106)

  • 21. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
    Wu-Wong JR; Melnick J
    Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Effect of vitamin D on kidney and cardiovascular system].
    Fujii H
    Clin Calcium; 2010 Jul; 20(7):1045-50. PubMed ID: 20585183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D receptor activation: clinical outcomes.
    Covic A; Apetrii M
    Contrib Nephrol; 2011; 171():166-171. PubMed ID: 21625107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
    Matuszkiewicz-Rowińska J; Żebrowski P
    Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
    Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M
    Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin D and proteinuria: a critical review of molecular bases and clinical experience.
    Pérez-Gómez MV; Ortiz-Arduán A; Lorenzo-Sellares V
    Nefrologia; 2013; 33(5):716-26. PubMed ID: 24089164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of vitamin d receptor activators in cardio-renal syndromes.
    Cozzolino M; Bruschetta E; Stucchi A; Ronco C; Cusi D
    Semin Nephrol; 2012 Jan; 32(1):63-9. PubMed ID: 22365164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.
    Andress DL
    Kidney Int; 2006 Jan; 69(1):33-43. PubMed ID: 16374421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation.
    Bover J; Cozzolino M
    Kidney Int Suppl (2011); 2011 Sep; 1(4):122-129. PubMed ID: 25018911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D and vitamin D receptor activators in treatment of hypertension and cardiovascular disease.
    Franczyk A; Stolarz-Skrzypek K; Wesołowska A; Czarnecka D
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):34-44. PubMed ID: 24597598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reprint of: Vitamin D receptor activation and prevention of arterial ageing.
    Cozzolino M; Stucchi A; Rizzo MA; Soldati L; Cusi D; Ciceri P; Brenna I; Elli F; Gallieni M
    Nutr Metab Cardiovasc Dis; 2013 Dec; 23 Suppl 1():S31-6. PubMed ID: 23199645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects.
    Wu-Wong JR; Kawai M; Chen YW; Nakane M
    Br J Pharmacol; 2011 Sep; 164(2b):551-60. PubMed ID: 21557735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy.
    Tan X; Li Y; Liu Y
    J Am Soc Nephrol; 2006 Dec; 17(12):3382-93. PubMed ID: 17082242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.
    Brancaccio D; Cozzolino M; Pasho S; Fallabrino G; Olivi L; Gallieni M
    Contrib Nephrol; 2009; 163():219-226. PubMed ID: 19494617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress in therapy of CKD-MBD with vitamin D receptor activators].
    Shoji T
    Clin Calcium; 2012 Jul; 22(7):1073-81. PubMed ID: 22750940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of vitamin D in the pathogenesis of chronic kidney disease].
    Cozzolino M; Brunini F; Capone V; Ricca F; Kwaidri Y; Montanari E; Cusi D
    Recenti Prog Med; 2013 Jan; 104(1):33-40. PubMed ID: 23439539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis.
    Piñera-Haces C; Izquierdo-Ortiz MJ; Martín-de Francisco ÁL; García-Unzueta MT; López-Hoyos M; Toyos C; Allende N; Quintela E; Arias M
    Nefrologia; 2013 Jan; 33(1):77-84. PubMed ID: 23364629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.
    Duplancic D; Cesarik M; Poljak NK; Radman M; Kovacic V; Radic J; Rogosic V
    Clin Interv Aging; 2013; 8():149-56. PubMed ID: 23430986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D receptor activators can protect against vascular calcification.
    Mathew S; Lund RJ; Chaudhary LR; Geurs T; Hruska KA
    J Am Soc Nephrol; 2008 Aug; 19(8):1509-19. PubMed ID: 18448587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.